Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Dri Healthcare Trust announced it has entered into agreements to buy royalty rights for the drug Tavapadon from Bain and Novaquest for US$316 million. The trust will receive tiered royalty payments on U.S. net sales of Tavapadon, including four annual fixed payments of $23.40 million post U.S. Food and Drug Administrat
Dri Healthcare Trust (TSX:DHT.U) announced a US$316 million purchase of the Tavapadon royalty.
DRI Healthcare Trust agreed to buy U.S. royalty participation rights on Parkinson’s candidate tavapadon for USD 316 million. Closing is contingent on FDA approval, expected in Q3 2026, along with other customary conditions. Deal includes tiered royalties on annual U.S. net sales at mid-single digit to low-double digit